tiprankstipranks
Trending News
More News >

Applied Molecular downgraded to Market Perform from Outperform at SVB

SVB Securities analyst Joseph Schwartz downgraded Applied Molecular Transport to Market Perform from Outperform with a price target of $2, down from $15, after the company announced the Phase 2 LOMBARD trial of its lead candidate AMT-101 in monotherapy for treating ulcerative colitis did not meet the primary endpoint.

Confident Investing Starts Here:

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on AMTI:

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1